Compare Recursion Pharmaceuticals Inc (RXRX) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.25 (market cap $1.86B), while ABRDN Physical Gold Shares ETF trades at $42.08. The key difference: ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SGOL | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $51.41 |
52-Week Low | $2.84 | $34.68 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
SGOL is trading at $41.48, down 1.78% with a bearish technical outlook as moving averages signal selling pressure. The stock faces resistance at $42 with support at $41, while RSI indicators show mixed signals. Recent news highlights institutional optimism for gold's medium-term prospects despite near-term volatility, with Goldman Sachs forecasting $4,900/oz gold by year-end.
The outlook remains cautiously optimistic as gold benefits from macroeconomic support including debt concerns and central bank demand. Key risks include Fed policy uncertainty and dollar strength, while technical weakness suggests potential for further consolidation before sustained upward movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
